The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A single-institution phase II trial of five fractions of radiotherapy followed by four courses of FOLFOX chemotherapy as preoperative therapy for rectal adenocarcinoma.
Robert J. Myerson
No relevant relationships to disclose
Parag J Parikh
No relevant relationships to disclose
Benjamin Tan
No relevant relationships to disclose
Steven Hunt
No relevant relationships to disclose
James W Fleshman
No relevant relationships to disclose
Elisa H Birnbaum
No relevant relationships to disclose
Matthew G Mutch
No relevant relationships to disclose
Ira J Kodner
No relevant relationships to disclose
Bashar Safar
No relevant relationships to disclose
Michael Naughton
No relevant relationships to disclose
Joel Picus
No relevant relationships to disclose
Steven Sorscher
No relevant relationships to disclose
Albert Craig Lockhart
No relevant relationships to disclose
Caron Rigden
No relevant relationships to disclose
Rama Suresh
No relevant relationships to disclose
Andrea Wang-Gillam
No relevant relationships to disclose
Lannis Hall
No relevant relationships to disclose